TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 7473014
Drug: Fiber therapy
Normalized name: Fiber Therapy
DrugBank: Calcium polycarbophil (DB14684)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fiber therapy alone for 20 days (FF)
Study: 1782132
Drug: Aggressive dietary
Normalized name: sodium phosphate, monobasic
DrugBank: Sodium phosphate, monobasic (DB09449)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Aggressive dietary management and treatment with pancreatic enzymes
Study: 7025721
Drug: Oral trimethoprim-sulfamethoxazole
Normalized name: sulfamethoxazole / trimethoprim
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral trimethoprim-sulfamethoxazole treatment
Study: 26061572
Drug: Benzocaine 20%
Normalized name: BENZOCAINE 20% GEL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Benzocaine 20% topical anesthetic
Study: 19697825
Drug: Patient-controlled continuous
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patient-controlled continuous epidural analgesia (PCEA) with 0.125% bupivacaine and 0.2 microg kg(‐1) fentanyl (basic infusion 1 mL h(‐1), bolus 4 mL, lock‐out time 15 min)
Study: 19697825
Drug: Remifentanil PCA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Remifentanil PCA (0.2 microg kg(‐1) bolus doses, without basic infusion, lock‐out time 2 min)
Study: 17896891
Drug: Rifaximin 200
Normalized name: rifAXIMin 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rifaximin 200 mg every 8 hours for 7 days
Study: 17896891
Drug: Single-dose intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single-dose intravenous midazolam 2 mg
Study: 17896891
Drug: Single-dose oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single-dose oral midazolam 6 mg
Study: 11927450
Drug: 0.1 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.1 mg/kg morphine
Study: 9652875
Drug: Nifedipine 30
Normalized name: nifedipine 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nifedipine 30 mg/d for 1 year
Study: 7661159
Drug: Omeprazole 20
Normalized name: omeprazole 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omeprazole 20 mg b.i.d. with 1 g amoxicillin b.i.d.
Study: 7661159
Drug: High dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose ranitidine (900 and 1800 mg) plus sodium bicarbonate tablets 650 t.i.d. with 1 g amoxicillin b.i.d.
Study: 1693732
Drug: Felodipine ER
Normalized name: Felodipine ER
Approvals — FDA: no, EMA: no, PMDA: no
Description: Felodipine ER 20 mg
Study: 21788
Drug: Lidocaine solution
Normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lidocaine solution with adrenaline plus Betadrenol (beta-receptor blocker)
Study: 21788
Drug: Lidocaine solution
Normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lidocaine solution with adrenaline
Study: 24151273
Drug: Low-dose radial
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose radial extracorporeal shock-wave therapy (rESWT) - three sessions at an interval of 10 to 14 days, 2000 pulses, 0.11 mJ/mm², 8 Hz
Study: 17967230
Drug: Trimetazidine (loading
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trimetazidine (loading dose of 60 mg followed by 20 mg 3 times daily for 2 weeks)
Study: 11240234
Drug: Adjuvant hormone
Normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Adjuvant hormone therapy (goserelin)
Study: 9469326
Drug: Low-dose EPO
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose EPO (2,000 U subcutaneously thrice weekly)
Study: 9469326
Drug: High-dose EPO
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose EPO (10,000 U subcutaneously thrice weekly)
Study: 9469326
Drug: Patients not
Normalized name: Lamictal 25mg-100mg Tablet Starter Kit (For Patients Not Taking Enzyme-Inducing Drugs or Valproate)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients not treated with chemotherapy (control group)
Study: 1967227
Drug: Esmolol 80
Approvals — FDA: no, EMA: no, PMDA: no
Description: Esmolol 80 mg bolus followed by 24 mg.min‐1 infusion
Study: 29972085
Drug: Randomised controlled
Normalized name: jojoba oil, randomized
Approvals — FDA: no, EMA: no, PMDA: no
Description: Randomised controlled trial of psychotherapy for treatment-resistant depression
Study: 29066863
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg MB12066 twice daily for 8 days
Study: 25909794
Drug: ω‐3 polyunsaturated
Approvals — FDA: no, EMA: no, PMDA: no
Description: ω‐3 polyunsaturated fatty acids (PUFAs), 1 capsule/day for three months
Study: 25909794
Drug: Traditional hypoglycemic
Normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Traditional hypoglycemic therapy
Study: 23707209
Drug: Herbal combination
Normalized name: HERBAL MISCELLANEOUS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Herbal combination of Mentha longifolia, Cyperus rotundus, and Zingiber officinale
Study: 15848533
Drug: Early steroid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Early steroid withdrawal protocol using basiliximab, CsA (8 mg/kg), MMF (2000 mg), and methylprednisolone (500 mg) rapidly tapered and withdrawn at 14 POD
Study: 15848533
Drug: Triple regimen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triple regimen consisting of CsA (same dose), MMF (same dose), and methylprednisolone (250 mg) tapered and continued
Study: 15848533
Drug: Early steroid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Early steroid withdrawal protocol using basiliximab
Study: 11042565
Drug: Gemcitabine 1000
Normalized name: gemcitabine 1000 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gemcitabine 1000 mg/m² on Days 1, 8, and 15 plus cisplatin 80 mg/m² on Day 2 (arm A)
Study: 9493664
Drug: Comprehensive out-patient
Normalized name: Cough Out
DrugBank: Guaifenesin (DB00874)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Comprehensive out-patient rehabilitation programme (physical training, occupational therapy, education, smoking cessation therapy) for 12 weeks
Study: 3553220
Drug: Bromocriptine (2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bromocriptine (2.5 mg/dose)
Study: 2502583
Drug: All doses
Normalized name: All Clear
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All doses of rIFN‐gamma
Study: 23240637
Drug: Breast cancer
Normalized name: chicken breast preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Breast cancer characteristics and treatment
Study: 21284660
Drug: Topical slimming
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical slimming cream
Study: 19631292
Drug: VSL#3 (3.6
Approvals — FDA: no, EMA: no, PMDA: no
Description: VSL#3 (3.6 x 10(12) CFU, twice daily for 12 weeks)
Study: 15045624
Drug: Triamcinolone hexacetonide
Normalized name: Triamcinolone Hexacetonide
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Triamcinolone hexacetonide (THA) 20 mg (1 ml)
Study: 15045624
Drug: Methylprednisolone acetate
Normalized name: methylprednisolone acetate
DrugBank: Methylprednisolone (DB00959)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Methylprednisolone acetate (MPA) 40 mg (1 ml)
Study: 11124794
Drug: Low dose
Normalized name: Low Dose ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dose ethinyloestradiol 50‐75 ng/kg/day, GH 28 IU/m(2) surface area/week as a daily injection
Study: 11124794
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of ethinyloestradiol and GH
Study: 11124794
Drug: Low dosage
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dosage ethinyloestradiol
Study: 7857363
Drug: 1200 mg/day
Normalized name: Rebetron, single dose 1200 mg/day oral and injectable kit
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1200 mg/day GEM
Study: 31468636
Drug: NAR150 (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: NAR150 (150 mg)
Study: 31468636
Drug: NAR600 (600
Approvals — FDA: no, EMA: no, PMDA: no
Description: NAR600 (600 mg)
Study: 31468636
Drug: NAR300 (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: NAR300 (300 mg)
Study: 31468636
Drug: NAR900 (900
Approvals — FDA: no, EMA: no, PMDA: no
Description: NAR900 (900 mg)
Study: 31044290
Drug: THC-dominant cannabis
Normalized name: Medical Cannabis
DrugBank: Medical Cannabis (DB14009)
Approvals — FDA: no, EMA: no, PMDA: no
Description: THC-dominant cannabis (125 mg, 11% THC; < 1% CBD)
Study: 31044290
Drug: THC/CBD equivalent
Approvals — FDA: no, EMA: no, PMDA: no
Description: THC/CBD equivalent cannabis (125 mg, 11% THC, 11% CBD)
Study: 28727817
Drug: Full dose
Normalized name: BayRHo-D Full Dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Full dose DgDgM_M
Study: 28727817
Drug: Full dose
Normalized name: BayRHo-D Full Dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Full dose DgDgMM_M
Study: 28727817
Drug: 3rd dose
Normalized name: CEPHALOSPORIN 3RD GENERATION
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3rd dose of MVA
Study: 25437881
Drug: Rosuvastatin calcium,
Normalized name: Rosuvastatin Calcium, 5 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rosuvastatin calcium, 20mg daily
Study: 17316364
Drug: Nonplatinum therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nonplatinum therapy
Study: 17316364
Drug: Platinum combination
Normalized name: platinum
DrugBank: Platinum (DB12257)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Platinum combination therapy
Study: 11748394
Drug: Lidocaine with
Normalized name: Lidocaine with Tegaderm
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lidocaine with clonidine (10 microg/ml)
Study: 8049313
Drug: tegafur 600
Normalized name: tegafur
DrugBank: Tegafur (DB09256)
Approvals — FDA: no, EMA: yes, PMDA: no
Description: tegafur 600 mg orally daily for two years
Study: 8049313
Drug: tegafur‐uracil 600
Approvals — FDA: no, EMA: no, PMDA: no
Description: tegafur‐uracil 600 mg orally daily for two years
Study: 8049313
Drug: mitomycin C
Normalized name: Mitomycin C
DrugBank: Mitomycin (DB00305)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: mitomycin C 20 mg intravenous bolus on the day of operation and 10 mg on the first postoperative day, plus mitomycin C 10 mg every three months for stage IV patients
Study: 3133211
Drug: Transdermal nitroglycerin
Normalized name: nitroglycerin Transdermal System
DrugBank: Nitroglycerin (DB00727)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transdermal nitroglycerin (5-15 mg)
Study: 27987231
Drug: Levodopa-entacapone-carbidopa intestinal
Normalized name: carbidopa / entacapone / levodopa
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levodopa-entacapone-carbidopa intestinal gel after a 20% dose reduction
Study: 27987231
Drug: Levodopa-carbidopa intestinal
Normalized name: carbidopa / levodopa
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levodopa-carbidopa intestinal gel (usual dose)
Study: 17688757
Drug: Impact of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Impact of pain on activities of daily living
Study: 11802939
Drug: Mycobacterium vaccae
Normalized name: Mycobacterium vaccae
DrugBank: Mycobacterium vaccae (DB18449)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mycobacterium vaccae vaccine (M. vaccae vaccine) with chemotherapy regimen of 2HRZE/2HR for 6 months
Study: 11802939
Drug: Chemotherapy regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy regimen of 2HRZE/4HR
Study: 2972790
Drug: Both subcutaneous
Normalized name: Bothrops atrox venom
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both subcutaneous heparin and stockings
Study: 27535481
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg oral micronized progesterone
Study: 20667937
Drug: Niacin (1500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Niacin (1500 mg/day over 8 weeks, maintained for 12 weeks)
Study: 18687278
Drug: Conservative treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conservative treatment options for osteoarthritis, specific interventions not detailed.
Study: 18687278
Drug: Traditional medical
Normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Traditional medical approach to management of OA, specific medications not detailed.
Study: 12897033
Drug: 6 microm
Normalized name: SODIUM POLYACRYLATE STARCH (25 MICROMETER PARTICLE)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6 microm albuterol aerosol at 20 microg
Study: 12897033
Drug: 3 microm
Normalized name: SODIUM POLYACRYLATE STARCH (25 MICROMETER PARTICLE)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 microm albuterol aerosol at 20 microg
Study: 12897033
Drug: 1.5 microm
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.5 microm albuterol aerosol
Study: 10821987
Drug: Oral nalmefene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral nalmefene 50 mg
Study: 10821987
Drug: Oral nalmefene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral nalmefene 100 mg
Study: 10475315
Drug: Intravenous morphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous morphine 10 mg
Study: 10821987
Drug: Intravenous morphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous morphine 20 mg
Study: 10821987
Drug: Oral nalmefene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral nalmefene 0 mg (placebo)
Study: 8444696
Drug: Acute acetazolamide
Normalized name: Acetazolamide
DrugBank: Acetazolamide (DB00819)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Acute acetazolamide (500 mg iv)
Study: 8444696
Drug: Chronic acetazolamide
Normalized name: Acetazolamide
DrugBank: Acetazolamide (DB00819)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Chronic acetazolamide (500 mg po every 6 h)
Study: 30902738
Drug: n-3 polyunsaturated
Normalized name: Omega-3 (n-3) polyunsaturated fatty acids
Approvals — FDA: no, EMA: no, PMDA: no
Description: n-3 polyunsaturated fatty acids (2 g per day of eicosapentaenoic acid (EPA) and 1 g of DHA)
Study: 24359500
Drug: GSK239512 (10-20-40-80
Approvals — FDA: no, EMA: no, PMDA: no
Description: GSK239512 (10-20-40-80 µg)
Study: 22077482
Drug: 40 mg
Normalized name: rutin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mg oral phytoestrogen (Promensil)/day
Study: 22077482
Drug: 80 mg
Normalized name: RNA 180 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 80 mg oral phytoestrogen (Promensil)/day
Study: 22077482
Drug: 0.05 mg
Normalized name: biotin 0.05 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.05 mg transdermal oestrogen/day
Study: 22077482
Drug: 0.1 mg
Normalized name: biotin 0.1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.1 mg transdermal oestrogen/day
Study: 7624601
Drug: Combined astemizole,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined astemizole, 20 mg, and ranitidine, 600 mg
Study: 2655611
Drug: Cicletanine 200
Normalized name: cicletanine
DrugBank: Cicletanine (DB12766)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cicletanine 200 mg/d
Study: 2655611
Drug: Cicletanine 50
Normalized name: cicletanine 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cicletanine 50 mg/d and 100 mg/d
Study: 31025253
Drug: Self-help Cognitive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Self-help Cognitive Behavioral Therapy (CBT) workbook
Study: 25972136
Drug: Micronized purified
Normalized name: RAYON,PURIFIED
Approvals — FDA: no, EMA: no, PMDA: no
Description: Micronized purified flavonoid fraction (MPFF; Daflon® 500 mg)
Study: 12687289
Drug: TJ-14 (7.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: TJ-14 (7.5 g/day)
Study: 8335984
Drug: Cold-adapted reassortant
Normalized name: human-bovine reassortant rotavirus strain G4 vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cold-adapted reassortant influenza B/Yamagata/10/88 virus vaccine
Study: 3567042
Drug: Intravenous midazolam
Normalized name: Midazolam
DrugBank: Midazolam (DB00683)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intravenous midazolam (15 mg)
Study: 3567042
Drug: Oral midazolam
Normalized name: Midazolam
DrugBank: Midazolam (DB00683)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Oral midazolam (15 mg)
Study: 22008247
Drug: Daily anticholinergic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily anticholinergic therapy plus a single intra‐detrusor injection of saline
Study: 22008247
Drug: Single intra‐detrusor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single intra‐detrusor injection of 100 U of botulinum toxin A plus daily oral placebo tablets
Study: 21053477
Drug: Omeprazole plus
Normalized name: Omeprazole
DrugBank: Omeprazole (DB00338)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Omeprazole plus bicarbonate powder (OBA: omeprazole 20 mg, sodium bicarbonate 1680 mg, alginic acid 250 mg)
Study: 21053477
Drug: Omeprazole capsules
Normalized name: Omeprazole
DrugBank: Omeprazole (DB00338)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Omeprazole capsules (OMZ: omeprazole 20 mg)
Study: 21053477
Drug: Omeprazole capsules
Normalized name: Omeprazole
DrugBank: Omeprazole (DB00338)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Omeprazole capsules (OMZ)
Study: 10100180
Drug: Estroprogestin replacement
Approvals — FDA: no, EMA: no, PMDA: no
Description: Estroprogestin replacement therapy (ERT)
Study: 8914118
Drug: Cyanocobalamin (CB12)
Normalized name: Cyanocobalamin
DrugBank: Cyanocobalamin (DB00115)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cyanocobalamin (CB12) 3 mg for 14 days
Study: 8914118
Drug: Methylcobalamin (MB12)
DrugBank: Mecobalamin (DB03614)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Methylcobalamin (MB12) 3 mg for 14 days
Study: 8914118
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (pre-treatment observation for 9 days)
Study: 1860150
Drug: Edmonston-Zagreb (E-Z)
Normalized name: measles virus vaccine live, Enders' attenuated Edmonston strain / mumps virus vaccine live, Jeryl Lynn strain / rubella virus vaccine live (Wistar RA 27-3 strain) / varicella-zoster virus vaccine live (Oka-Merck) strain Injection [ProQuad]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Edmonston-Zagreb (E-Z) vaccine, 3.9 log 50 infectious units
Study: 1860150
Drug: Schwarz vaccine,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Schwarz vaccine, 3.28 log 50 infectious units
Study: 9758290
Drug: 500 mg
Normalized name: bran 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500 mg amoxicillin
Study: 7173186
Drug: 125 mg
Normalized name: niacin 125 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 125 mg potassium clavulanate
Study: 7173186
Drug: 625 mg
Normalized name: betaine 625 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 625 mg amoxicillin and potassium clavulanate combination (augmentin)
Study: 7173186
Drug: Control (administration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (administration alone)
Study: 31812956
Drug: Intensive blood
Normalized name: dragon's blood extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intensive blood pressure management (target SBP 130-140 mm Hg) with standard-dose alteplase (0.9 mg/kg)
Study: 31812956
Drug: Intensive blood
Normalized name: dragon's blood extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intensive blood pressure management (target SBP 130-140 mm Hg) with low-dose alteplase (0.6 mg/kg)
Study: 31812956
Drug: Guideline-recommended blood
Normalized name: dragon's blood extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Guideline-recommended blood pressure management (target SBP <180 mm Hg) with standard-dose alteplase (0.9 mg/kg)
Study: 31812956
Drug: Guideline-recommended blood
Normalized name: dragon's blood extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Guideline-recommended blood pressure management (target SBP <180 mm Hg) with low-dose alteplase (0.6 mg/kg)
Study: 21523893
Drug: Biodegradable polymer-based
Normalized name: dicresulene polymer
Approvals — FDA: no, EMA: no, PMDA: no
Description: Biodegradable polymer-based sirolimus-eluting stent with six months of dual antiplatelet therapy (clopidogrel and aspirin)
Study: 22945767
Drug: Prolonged clopidogrel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prolonged clopidogrel therapy (>6 months)
Study: 8314425
Drug: Intensified treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intensified treatment
Study: 17335116
Drug: Spirulina (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Spirulina (3 g/day)
Study: 15489477
Drug: Periocular injections
Normalized name: autologous human adipose perivascular stromal cells genetically modified to secrete soluble tumour necrosis factor-related apoptosis-inducing ligand
DrugBank: RR001 (DB17369)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Periocular injections of triamcinolone acetate (20 mg, 40 mg/ml)
Study: 7830631
Drug: Psyllium cereal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Psyllium cereal (50 g containing 12 g soluble fibre)
Study: 7830631
Drug: Wheat cereal
Normalized name: WHEAT
DrugBank: Wheat (DB10579)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Wheat cereal (60 g containing 2 g soluble fibre)
Study: 26453641
Drug: ONO-9054 morning
Approvals — FDA: no, EMA: no, PMDA: no
Description: ONO-9054 morning dosing (1 drop to each eye at 07:00)
Study: 26453641
Drug: ONO-9054 evening
Normalized name: Evenity
DrugBank: Romosozumab (DB11866)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: ONO-9054 evening dosing (1 drop to each eye at 19:00)
Study: 26453641
Drug: Vehicle (placebo)
Normalized name: meningococcal group B vaccine / Neisseria meningitidis serogroup B recombinant FHBP fusion protein antigen / Neisseria meningitidis serogroup B recombinant NHBA fusion protein antigen / Neisseria meningitidis serogroup B strain NZ98/254 outer membrane vesicle Prefilled Syringe [Bexsero]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vehicle (placebo) evening dosing
Study: 22092389
Drug: 2.5 mL
Normalized name: syringe, disposable, 2.5 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2.5 mL of 2% lidocaine (low volume-high concentration)
Study: 22092389
Drug: 5 mL
Normalized name: WATER,INHL 5 ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mL of 1% lidocaine (high volume-low concentration)
Study: 16809351
Drug: BioBran MGN-3
Normalized name: MGN-4893
DrugBank: MGN-4893 (DB17338)
Approvals — FDA: no, EMA: no, PMDA: no
Description: BioBran MGN-3 (2 g three times per day for 8 weeks)
Study: 1996592
Drug: Fludarabine 30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fludarabine 30 mg/m2 over 30 minutes daily for 5 days every 4 weeks
Study: 1996592
Drug: Fludarabine 30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fludarabine 30 mg/m2 over 30 minutes daily for 5 days every 4 weeks with prednisone
Study: 28684371
Drug: Fludarabine therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fludarabine therapy
Study: 16294079
Drug: Nebulized morphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nebulized morphine every 4 hours
Study: 1809429
Drug: Patient-controlled analgesia
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patient-controlled analgesia (PCA) morphine
Study: 11786571
Drug: Five-drug induction
Normalized name: fivehorn smotherweed pollen extract Injectable Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Five-drug induction regimen (standard or intensive timing)